Slide 1 Review Continued
The term AML, M1 or M2 relates to the French-American-British (FAB) groups classification of Acute Leukaemia's and Myelodysplastic Syndromes. The FAB classification was developed in the 1970’s firstly as an aid to differentiate Acute Lymphoid from Acute Myeloid Leukaemia, classification is based solely on the cytochemical morphology of cells to elucidate their lineage and maturation. In the 1980’s further development of the FAB classification sub divided the Acute Myeloid Leukaemia's into 8 categories based upon the morphological features of the cells:
M0 – AML with minimal evidence of differentiation
M1 – Poorly differentiated no Myeloid maturation
M2 – Myeloblastic with some Myeloid maturation
M3 and M3v – Promyelocytic Leukaemia
M4 – Acute Myelomonocytic Leukaemia
M5a and M5b – Monoblastic Leukaemia
M6 – Erythroblastic Leukaemia
M7 – Megakaryoblastic Leukaemia
With the development of techniques such as cytogenetics and immunophenotyping, the World Health Organisation (WHO) proposed a new classification which was based on the genetic, immunophenotypic, biological and clinical features of patients to better define specific disease entities.
The WHO classification of AML (briefly)
AML with myelodysplastic syndrome, therapy related.
AML with recurrent genetic abnormalities e.g. AML with t(8;21)(q22;q22), AML1(CBFA)-ETO fusion gene, Acute Promyelocytic Leukaemia (AML with t(15;17)(q22;q11-12) and PML-RARA fusion gene or variants with RARA.
AML with multilineage myelodysplasia.
AML Not Otherwise Categorised. In such cases the FAB classification is used.
|